Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

• Status: Completed
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Affymax

Criteria

Main eligibility criteria:

• Participant is a healthy male, age ≥ 18 years and ≤ 40 years, with body mass index (BMI) ≥ 18 and ≤ 30 kilograms per squared meter (kg/m^2), and weight ≥ 50 and ≤ 95 kilograms (kg)

• Participant has hemoglobin of ≤ 16 grams per deciliter (g/dL) at the time of study entry

• Participant has normal iron stores